MEDI4276 (trastuzumab scFv with AZ13599185, a tubulysin payload), PF-06804103 (anti-Trop2 Aur0101), A166 (undisclosed payload), ALT-P7 (HM2-monomethyl auristatin E), ARX 788 (monoclonal antibody with monomethyl auristatin E), DHES0185A (monoclonal antibody with benzodiazepine monoamide), and SYD 985 (trastuzumab duocarmazine with seco-DUBA) are other ADCs under investigation for HER2+ BC [42,56,57,58,59,60,61,62]. Here, ERBB2 is linked to breast cancer.